The aim was to evaluate the efficacy of standardised Manuka (Leptospermum species) antibacterial honey as adjunctive twice daily treatment to conventional therapy (warm compresses, lid massage and preservative-free lubricant), in participants with evaporative dry eye due to moderate to advanced meibomian gland dysfunction.
Meibomian gland dysfunction (MGD) is characterised by chronic, diffuse functional abnormalities of the meibomian glands and altered secretion quality and expressibility. 1 MGD leads to increased tear evaporation, increased tear osmolarity and an increased susceptibility to ocular surface inflammation, ocular surface epithelial damage and discomfort. 1 MGD is recognised as the leading cause of evaporative dry eye disease 1, 2 and affects between four per cent and 20 per cent of Caucasians and more than 60 per cent of Asians. 3 Conventional evidencebased therapy for obstructive MGD (warm compresses and eyelid massage and lipidcontaining lubricants) is limited in efficacy in moderate to advanced disease. 4, 5 Adherence to prolonged, time-consuming homebased therapies is traditionally poor. 4, 5 Prescription medications (topical steroids, topical and oral antibiotics and topical immunomodulatory agents) and oral omega 3 essential fatty acids have demonstrated efficacy in reducing symptoms and signs of MGD;
2,4-7 however, side effects, adverse effects, development of antibiotic resistance, pregnancy and lactation contraindications, cost, lack of reimbursement, availability of commercial versions, off-label use and need for ongoing treatment are issues that can limit their long-term use. pulsation 8 and intense pulsed light therapy 9 potentially offer sustained (three to six months) improvements in symptoms and signs. Currently, limitations to these treatments include expense of the LipiFlow device and consumables, 10 lack of efficiency of LipiFlow in advanced disease, 9 multiple treatments are required before clinical improvements are achieved with intense pulsed light 11 and individuals with dark African skin phototype, those using photosensitising medications and having photosensitising conditions, are excluded from treatment. 11 Honey has a long history in eye care and wound care. 12, 13 Honey is a supersaturated solution of sugars with an acidic pH, high osmolarity and low water content and can inhibit the growth of microorganisms, reduce oedema and promote epithelialisation. 12, 13 Honey from a variety of floral sources and geographic locations and in a range of concentrations, has been used in the chronic management of ocular surface diseases, including post-operative corneal oedema and bullous keratopathy, 14, 15 Sjög-ren's and non-Sjögren's aqueous deficient dry eye, 14, 16 evaporative dry eye due to MGD, 14, 16 neurotrophic keratitis, 17 vernal keratoconjunctivitis, 18 contact lens-related microbial keratitis 19 and as antimicrobial prophylaxis for eye surgery. 20 Two standardised Leptospermum species (spp.) antibacterial medical honey products are regulatory approved as medical devices to treat dry eye disease associated with MGD in Australia, New Zealand and Europe: Optimel Antibacterial Manuka Eye Gel (98 per cent Leptospermum spp. honey, Melcare Biomedical Pty Ltd, Brisbane, Australia) and Optimel Manuka + Dry Eye Drops (16 per cent Leptospermum spp. honey, Melcare Biomedical Pty Ltd). These medically regulated Leptospermum spp. antibacterial honey products have numerous practical advantages in the chronic care of dry eye and MGD: low cost, over-the-counter, sterile, non-preserved (gel product) and non-benzalkonium chloride preserved (eye drop product), non-cytotoxic with frequent dosing and long-term dosing, multidose, broad spectrum, unaffected by standard room temperature (being most active at 25 C) and unaffected by UV and extended shelf life. [12] [13] [14] 17, 21 Leptospermum spp. honeys can also be used concurrently with topical lubricant, antimicrobial, antiglaucoma and anti-inflammatory therapies. 14, 16, 17 Currently, there are few published clinical studies on the efficacy of antibacterial honeys in eye care and none involving use of regulatory-approved honey products for dry eye due to MGD. This prospective randomised controlled clinical trial assessed the efficacy of standardised Leptospermum spp. antibacterial honey eye gel and eye drop products as adjunctive therapy to conventional treatment for MGD (warm compresses, lid massage and lubricants) in participants with evaporative dry eye due to moderate to advanced MGD. 
METHODS

Participants
Adult participants (n = 114, aged 20 to 92 years, 83 female, 102 Caucasian) with a clinical diagnosis of moderate to severe evaporative dry eye due to MGD were recruited (Table 1) .
Exclusion criteria were: hypersensitivity or allergy to honey or bee products; active infection of the eye or adnexae; ocular surgery, contact lens wear or punctal plug insertion within the previous six months; current or recent (within three months) use of topical eye drops other than ocular lubricants; planning a pregnancy, pregnant or lactating; and initiation of or alteration to the dose of a systemic medication known to affect tear production within 30 days of the initial assessment.
Dry eye due to MGD was diagnosed and staged on the severity scale (1 to 4) recommended by the Diagnosis Subcommittee of the International Workshop on Meibomian Gland Dysfunction, 22 presence of one or more Ocular Comfort Index (OCI) symptoms of ocular surface irritation ('dry', 'gritty', 'stingy', 'tired', 'painful', 'itching'), 23 tear film instability as measured by fluorescein break-up time less than 10 seconds, interpalpebral ocular surface fluorescein staining score 1 or more (Oxford Grading Scale) 24 and slitlamp biomicroscopic evidence of MGD, diffuse abnormalities of the meibomian glands, including qualitative and/or quantitative changes in meibum quality and gland expressibility. 22 Prior to recruitment, an instillation trial of each Optimel treatment product was performed to assess for a hypersensitive reaction (right eye received Optimel 16 per cent drops and left eye received 98 per cent gel). It was expected that the topical ocular use of honey would produce transient stinging and conjunctival inflammation. [13] [14] [15] [16] 25 If protracted inflammation and/or stinging (more than five minutes after instillation) was experienced or any late stage reactions were reported, the participant was excluded from further participation.
Treatments
Following recruitment, all participants commenced a wash-out period of two weeks involving the commencement of conventional MGD treatment. This treatment involved twice daily warm compresses (using a warm wet face cloth applied to the eyes, reheated if necessary to maintain warmth, for a total of five minutes) followed by gentle lid massage to both eyes. Preservative free lubricant (Systane Ultra [polyethylene glycol 400 0.4 per cent; propylene glycol 0.3 per cent], Alcon, Fort Worth, Texas, USA) was permitted to be used as required in both eyes. No other treatments were permitted.
Following these initial two weeks of conventional treatment, participants were advised to continue the conventional therapy for MGD and randomised to one of three treatment groups: Optimel products were applied twice daily to both eyes. Participants were required to keep a daily log of their adherence to treatment and topical lubricant use.
Six additional participants were recruited but did not complete the trial for the following reasons: unrelated illness requiring commencement of oral antibiotic medication (n = 1); non-adherence to conventional treatment (n = 2); intolerance to temporary stinging (without protracted redness) with repeated use of Optimel 16 per cent drops (n = 2) and Optimel 98 per cent gel (n = 1). The five per cent drop out rate (6/120) is less than that reported for other longitudinal studies of topical treatment for MGD. 7, 16 Only the data of the 114 participants that completed both the washout and treatment phases of the trial were included in the analyses (Table 1) .
Ocular surface assessments
The following subjective parameters were assessed at baseline (Week 0, following two weeks of conventional treatment) and at Week 8 (after commencing Optimel treatment).
Dry eye symptoms on a score of zero to 100 using validated dry eye symptoms surveys (Ocular Surface Disease Index [OSDI] 26 and OCI). 23 The scores of these questionnaires exhibit a positive correlation with each other with a high validity, reliability, specificity and sensitivity. 27 The OSDI assesses both the frequency of dry eye symptoms and their impact on activities of daily living and correlates moderately with clinical signs of moderate aqueous tear-deficient dry eye. 26 In the absence of a specific and validated questionnaire for symptoms of MGD, 1 the OCI, which assesses frequency and severity of nonsubtype specific symptoms of ocular surface irritation, 23 was also administered.
Daily lubricant use was assessed via participant log books.
The Schirmer I test of aqueous tear secretion (without anaesthetic, over five minutes) was performed. Values of less than 7.0 mm are considered diagnostic of aqueous tear deficiency. 28 Tear osmolarity was measured using the Tearlab Osmolarity System (Tearlab, San Diego, California, USA) (normal value less than 308 mOsmol/l). 29, 30 Central corneal sensation was measured with a 0.12 mm nylon monofilament (Cochet-Bonnet aesthesiometer, Luneau Ophthalmlogie, Chartres, France) (normal reference value 5.5 AE 0.8 cm). 31 InflammaDry (Rapid Pathogen Screening, Inc., Sarasota, Florida, USA) point-of-care immunoassay was used to detect elevated matrix metalloproteinase 9 (MMP-9 tear levels) (40 or more ng/mL). MMP-9 is an inflammatory biomarker that is elevated in the tears of patients with dry eyes. 32 All participants also underwent an anterior eye slitlamp examination. Ocular surface one per cent sodium fluorescein staining enhanced by a yellow Wratten filter (No. 12, Kodak) and cobalt light was graded using the Oxford Score (zero to 15 for the total exposed inter-palpebral conjunctiva and cornea). 24 Conjunctival bubar and limbal redness (vascular injection) were graded zero (normal), 1 (trace), 2 (mild), 3 (moderate), 4 (severe) according to the Efron Grading Scales. 33 Eyelid margin redness (vascularity) was graded zero (normal), 1 (mild engorgement), 2 (moderate engorgement), 3 (severe engorgement) with a score of 2 or more considered diagnostic of MGD. 34 Meibum quality was assessed in each of eight glands of the central third of the lower lid on a scale of zero to 3 for each gland: zero, clear; 1, cloudy; 2, cloudy with debris (granular); and 3, thick, like toothpaste (total score range, zero to 24). 22 Meibomian gland expressibility was assessed on a scale of zero to 3 in five glands on the central lower lid, according to the number of glands expressible: zero, all glands; 1, three to four glands; 2, one to two glands; and 3, no glands. 22 The overall severity of the MGD was assessed as Stage 1 (minimal) to Stage 4 (advanced) according to the guidelines of the International Workshop on Meibomian Gland Dysfunction based on symptoms, corneal staining and meibomian gland secretion quality and expressibility. 1 A swab of the lower eyelid margin in the most symptomatic eye or, if symptoms were equal, the eye with the greatest Oxford staining score, was taken for bacterial cultures and colony counts of the most dominant organisms using previously described methods. 16 With the exception of the lid margin swab, assessments were performed on both eyes of each participant at baseline: safety outcomes were assessed via ophthalmic examinations and the recording of any adverse events that occurred throughout the study.
Objective parameters were assessed by a single investigator to reduce inter-observer variability. In an attempt to avoid more invasive tests influencing the outcome of subsequent tests, the following testing order was used: symptom surveys, slitlamp examination to grade lid margin, bulbar and limbal redness, TearLab osmolarity, InflammaDry, Schirmer I, lid margin swab, fluorescein ocular surface staining, fluorescein breakup time, meibum quality and meibomian gland expressibility and corneal sensation.
Data analysis
The data on the participant's most symptomatic eye at baseline (or if symptoms were 
Power calculation
If the baseline OSDI is 40 AE 15 and a decrease of 10 in OSDI 27 is considered clinically relevant, then the power calculation gives n = 20, for a power 1 − β = 0.8 and α = 5 per cent. If a clinically relevant difference in treatment effect between groups is 10 on the OSDI, then the power calculation gives n = 36 in each group, for the same power.
RESULTS
Participant characteristics at baseline
The participants in the three treatment groups were of similar age, gender distribution and ethnicity. The participant cohort was predominantly middle aged, predominantly female and predominantly Caucasian (Table 1) . MGD severity stage and the need to use ocular lubricants also were similar. On average, participants had moderate to advanced staged MGD and used lubricants four times daily (Table 1) .
At baseline, the three groups were similar for all assessments of dry eye and MGD (Table 2) , except for the limbal and bulbar redness scores, which varied between the groups (p = 0.05). Limbal and bulbar redness scores were slightly higher for Optimel 98 per cent gel group.
Participants were highly symptomatic (OSDI score greater than 33 indicates severe dry eye) 26, 27 had normal aqueous tear production (Schirmer I test seven or more mm per five minutes), 28 normal tear osmolarity and very poor tear film stability. 22 Corneal sensitivity was normal 31 and moderate interpalpebral ocular surface staining was present. 1 Mild to moderate limbal, 33 bulbar 33 and lid margin redness 34 were present and 33 per cent of participants' tears had elevated levels of MMP-9.
32
The most dominant organisms cultured from the lid margins is listed in Table 3 . The most common cultured organism was the ubiquitous coagulase Staphylococcus epidermidis, which was present on the lid margins of 42 per cent of the participants and the next most common was Staphylococcus aureus with positive cultures in 20 per cent (Table 3) . Lid margin bacterial colony counts were high and variable (Table 4) . (Table 5 and Figure 1 ). Improvements on the OSDI were clinically significant 27 for all three treatment groups (16.4 AE 20.3, 12.7 AE 17.6 and 10.9 AE 26.0 for Optimel 98 per cent gel, Optimel 16 per cent drops and control groups, respectively; Table 6 ); the improvements across the three groups were not significantly different ( Figure 1A and Table 6 ). Improvements on the OCI were also not significantly different for the three treatment groups ( Figure 1B and Table 6 ). For the OSDI, 86, 81 and 60 per cent of participants reported a subjective improvement in the Optimel 98 per cent gel, Optimel 16 per cent drops and control groups, respectively; related numbers were 86, 84 and 82 per cent for the OCI. Only one participant in the Optimel 16 per cent drop group and two participants in the control group reported no improvement on either survey.
OBJECTIVE SIGNS
All three treatments significantly improved (p ≤ 0.05) the following objective signs of dry eye and MGD (Table 5) : meibum quality, tear osmolarity, fluorescein tear breakup time, corneal staining, limbal redness, bulbar redness, lid margin redness and InflammaDry. Meibomian gland expressibility score and InflammaDry were improved by both Optimel treatments (p ≤ 0.05) but not by the control treatment. None of the treatments improved tear production (based on the Schirmer I) or corneal sensitivity, which were normal at baseline and remained unchanged (Table 5) .
OSMOLARITY
All three treatments significantly (p ≤ 0.05) lowered tear osmolarity (Table 5 ). The improvements across the three groups were not significantly different (Table 6 and Figure 2A ). For all treatments the decrease in tear osmolarity was correlated to the baseline tear osmolarity (Optimel 98 per cent gel, R = 0.975, p < 0.001; Optimel 16 per cent drop, R = 0.773, p < 0.001; control, R = 0.605, p < 0.001).
FLUORESCEIN BREAK-UP TIME
All three treatments significantly increased (p ≤ 0.05) the tear break-up time ( Table 5 ). The improvements across the three groups were not significantly different (Table 6 and Figure 2B ).
MEIBUM QUALITY AND MEIBOMIAN GLAND EXPRESSIBILITY
All three treatments significantly improved (p ≤ 0.05) meibum quality (Table 5 and Figure 3B ). Both the Optimel treatments significantly improved meibomian gland expressibility but the control did not (Table 5 and Figure 3A ). There were significant differences in the abilities of the three treatments on both measures (Table 6) 
Staphylococcus aureus
BL: baseline assessment, None: no organisms cultured, W8: Week 8 assessment. 
INFLAMMATION
All three treatments significantly (p ≤ 0.05) improved lid margin redness, bulbar redness and limbal redness (Table 5 and Figure 4 ). There were no significant differences in the three treatments' abilities to impact either measure (Table 6 ). Tear MMP-9 expression was above threshold in significantly fewer participants with both Optimel 98 per cent gel and Optimel 16 per cent drops without any significant difference noted between the Optimel treatment groups in the ability to reduce MMP-9 expression.
CORNEAL STAINING
All three treatments significantly (p ≤ 0.05) improved interpalpebral staining (Table 5 ). There were significant differences in the three treatments' abilities to do this, with 
BACTERIAL COLONY COUNTS
Total lid margin bacterial colony counts for all bacterial species were significantly improved with Optimel 16 per cent drops but not Optimel 98 per cent gel or the control ( Table 5 ). The range of organisms cultured from the lid margins of participants both before and after treatment is shown in Table 5 ; the most commonly cultured organism was Staphylococcus epidermidis. The number of participants culturing no organisms increased slightly in all groups from 36 to 44 per cent, 30 to 46 per cent and 23 to 33 per cent for Optimel 98 per cent gel, Optimel 16 per cent and the control, respectively (Table 3) . For those participants culturing Staphylococcus epidermidis on the lid margins at baseline, a significant reduction in colony forming units was achieved at Week 8 compared with baseline for Optimel 16 per cent drops (p = 0.041) and Optimel 98 per cent gel (p = 0.027) but not the control group (p = 0.062); however, these reductions in colony counts were not significantly different between the treatment groups (p = 0.055) ( Table 3) .
LUBRICANT USE
Both Optimel treatments but not the control resulted in participants being able to reduce their daily lubricant use (Table 5 ). There were significant differences in the three treatments' abilities to reduce the need for lubricants, with Optimel 16 per cent having the greater effect (Table 6 and Figure 6 ). The control treatment did significantly reduce the need for lubricants ( 36 As a consequence of this increased enzyme activity, bacteria can change the viscosity of the meibum, leading to further stasis of the meibum within the meibomian glands and generate free . All three treatments significantly improved the subjective measures of dry eye disease. There were no significant differences for the subjective improvements of the three treatments. Data are mean and standard error. *p < 0.05. 
Symptomatic improvement
While subjective improvements with Optimel products over conventional therapy were not achieved according to the validated symptoms survey scores (OSDI, OCI) (Figure 1 ), over 20 per cent more participants in each Optimel treatment group reported symptomatic improvement in the OSDI compared with the control group. Additionally, twice daily use of Optimel honey 16 per cent significantly reduced the need for lubricants by approximately three instillations per day.
One of the major limitations of topical ophthalmic honey is the temporary redness . All three treatments significantly improved both the osmolarity (lowered) and the break-up time (increased). There were no significant differences among the measured improvements of the three treatments. Data are mean and standard error. *p < 0.05. Figure 3 . Frequency histograms of change in meibomian gland expressibility score (A) and change in meibum quality score (B) after the eight weeks of treatment. For both scores a reduction represents an improvement. All three treatments significantly improved meibum quality. Both Optimel treatment groups significantly improved meibum gland expressibility. The control group did not give a significant improvement for meibomian gland expressibility. There were significant differences in the three treatments on both measures. Optimel 98 per cent had a significantly greater effect on both meibomian gland expressibility and meibum quality.
Topical antibacterial Manuka honey treatment for dry eye due to MGD Albietz and Schmid
Clinical and Experimental Optometry 100.6 November 2017 © 2017 Optometry Australia and sting on instillation, which limit uniform acceptance and reduce long-term adherence to treatment; [13] [14] [15] [16] 25 however, our dropout rate due to stinging and redness in this study (five per cent) was much lower than in our pilot study. 16 This may be due to our improved participant education associated with the use of Optimel and increased participant acceptance associated with use of regulatory approved ophthalmic products.
Antimicrobial effects
In this study, use of Optimel 16 per cent drops significantly reduced total bacterial lid margin isolates (Table 5 ) and both Optimel products significantly reduced Staphylococcus epidermidis isolates (Table 4) . These results confirm those obtained in an earlier pilot study assessing the effect of thrice daily application of an unapproved pure medical grade Leptospermum spp. honey (Antibacterial Medical Honey, Medihoney, Comvita Pty Ltd, Paengaroa, New Zealand) on the ocular flora in patients with aqueous tear-deficient dry eye and/or MGD. 16 The acidic pH (mean 4.4), high osmotic concentration and low water content of pure raw honeys inhibit bacterial colonisation. 12, 13 Additional antimicrobial activity in some honeys, including Leptospermum spp. honey, is generated on dilution of honey by the activation of bee-derived glucose oxidase to produce low levels of hydrogen peroxide. 37, 38 On the ocular surface, this dilution is likely to occur with reflex tearing produced in response to the stinging from the low pH of the honey. Methylglyoxal [38] [39] [40] and cationic antimicrobial peptide bee defensin-1 38 also act as antibacterial substances in some honeys, including some Leptospermum spp. honeys.
Optimel products are prepared for medical use to a rigorous set of systems and standards from a unique proprietary mix of Australian and New Zealand Leptospermum spp. honeys. These honeys are selected for their highest and most consistent level of antibacterial activity, including activity against antibiotic-resistant strains such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. [41] [42] [43] [44] [45] Regulated medical grade honeys, such as Optimel are sterilised by gamma irradiation to destroy spore-forming organisms that may be present in the honey, without loss of antibacterial activity. 21 In vivo, Leptospermum scoparium (manuka) can inhibit a diverse range of bacterial pathogens, including multi-drug-resistant bacteria, 43, [45] [46] [47] prevent biofilm formation and disrupt pre-formed biofilms; [48] [49] [50] however, in our clinical study, there were single isolated cases of significant growth of Serratia Marcescens and Enterococcus spp. after eight weeks of Optimel gel and drop treatment, respectively (Table 4) . Figure 6 . Frequency histograms of change in daily lubricant use over the eight weeks of treatment. A reduction represents a decrease in the number of times per day an ocular lubricant was used. There were significant differences in the three treatments' abilities to reduce the need for lubricants, with Optimel 16 per cent having the greater effect. The control group did not significantly reduce the need for lubricants.
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Demodex folliculorum is thought to have a key role in the pathogenesis of chronic MGD and the associated chronic inflammatory dermatological condition, acne rosacea. 35, 36, 51, 52 While the efficacy of honey on Demodex spp. was not assessed in this study, a recent randomised controlled trial found that a 90 per cent medicalgrade New Zealand kanuka honey (floral source Kunzea ericoides bush) effectively treated rosacea. 53 In rosacea, antigenic proteins related to the bacterium Bacillus oleronius isolated from Demodex folliculorum are thought to exacerbate the inflammatory response. 51 The effect of medicalgrade honey on B. oleronius and the Demodex folliculum mite in MGD would be a potential avenue for further investigation. 53 
Anti-inflammatory effects
Some Leptospermum spp. honeys have immunomodulatory activity additional to their antimicrobial effects. [54] [55] [56] In this study, topical honey did not significantly reduce clinically observed signs of ocular surface inflammation (lid margin, bulbar or conjunctival redness) compared with the control; however, a significant reduction in the number of participants with the elevated tear cytokine MMP-9 occurred with use of each honey product (Table 5) . MMP-9 levels on the ocular surface are elevated in MGD. 57 MMP-9 is a non-specific biomarker for inflammation and is intimately associated with the other mediators of the inflammatory pathway on the ocular surface. 58 Hence, the reduced expression of MMP-9 with honey use suggests a potential anti-inflammatory role of Leptospermum spp. honey on the ocular surface.
Honeys from floral sources other than Leptospermum spp. have exhibited antiinflammatory effects in ocular surface disease (decreased conjunctival hyperaemia, 18, 59 decreased neutrophilic infiltration 59 and decreased corneal expression of vascular endothelial growth factor, transforming growth factor beta, interferon gamma, interleukin 12, chemokines and tumour necrosis factor alpha). 60 Further investigation is warranted to identify the active component(s) and mechanisms responsible for these antiinflammatory and wound-healing activities of honeys [59] [60] [61] on the ocular surface.
Effects on meibomian gland expressibility and secretion quality
Both Optimel treatments improved meibum quality and expressibility more effectively than control (Table 5 and Figures 3A  and 3B ). The more concentrated Optimel 98 per cent gel product was statistically more effective than Optimel 16 per cent or the control, improving these measures of meibomian gland function (Table 6) , with clinical improvements from Stage 1 to 2 (mildly altered expressibility) to Stage zero to 1 (normal expressibility) and from Stage 4 (severely altered secretions) to Stage 3 (moderately altered secretions) for meibum secretion quality. 1 The increased viscosity of the more concentrated honey product (which also contains a small amount of a naturally occurring gum to increase viscosity) and prolonged retention time on the ocular surface and lid margins is likely responsible for its increased clinical efficacy in this regard. The exact mechanism by which honey improves meibomian gland expressibility and secretion quality requires further investigation involving the use of confocal microscopy and lipid chemistry. A possible explanation for this is the hyperosmolar effect of honey reducing inflammation, oedema and obstruction at the meibomian gland orifices. Optimel 98 per cent gel has been demonstrated previously to temporarily but significantly reduce corneal epithelial oedema, 14 so it may be having a similar effect on the lid margin.
The stasis of the meibum in MGD is thought to promote increased meibum viscosity and bacterial growth on the lid margins, which generate free fatty acids, leading to inflammation and hyperkeratinisation of the gland orifices and a vicious cycle of further meibum stasis. 36 To fit with this current thinking regarding the pathogenesis of MGD, the improvement in meibomian gland expressibility with the Optimel 98 per cent gel correlated with the improvement in meibum quality and with the improvement in the ocular surface staining (epithelial damage) in our study.
Effects on ocular surface staining
Both honey products were superior to the control in reducing interpalpebral ocular Figure 7 . Inferior lid margin of a participant before (A) and after (B) eight weeks of Optimel 16 per cent honey eye drops used twice daily, as an adjunctive treatment to warm compress therapy and eyelid massage. Reduced conjunctival and lid margin redness and improved meibomian gland secretion quality were observed with the honey treatment.
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Clinical and Experimental Optometry 100.6 November 2017 © 2017 Optometry Australia surface epitheliopathy with Optimel 16 per cent drops being significantly more effective ( Figure 5 and Table 6 ). This improvement in superficial epitheliopathy adds to the growing body of evidence from clinical trials, 16 ,25 retrospective reviews, 14,15 case reports, 17, 19 animal models of wound healing 59, 60 and in vitro studies 63, 64 that honeys from a variety or floral sources and geographic locations and in varying concentrations can reduce corneal epitheliopathy, 14, 25 and promote corneal epithelialisation. 19, 59, 60 The immunomodulatory activity of honey is highly complex because of the involvement of multiple quantitatively variable compounds among honeys of different origins. 61 The high total sugar content of honey has been suggested to provide additional energy resources promoting epithelial wound closure 62 and the antimicrobial effects of honey may assist corneal epithelial wound healing by reducing bacterial colonisation. 62 The greater antibacterial effect of the more dilute Optimel 16 per cent drop in this study is a possible explanation for the greater efficacy of this product in reducing ocular surface staining. The identification of key compounds in honeys and their contributions to wound healing are ongoing 56, 57 and are crucial for a better understanding of the mechanisms underlying honey-mediated ocular surface wound healing and the role of honeys in restoring epithelial integrity.
Effects on tear osmolarity
Tear hyperosmolarity due to increased tear electrolytes, is a key pathogenic factor inducing inflammation in dry eye disease and MGD. 1, 35 Our participant cohort had normal baseline tear osmolarity (less than 308 mOsmol/L) 29 .30 possibly because they were using and continued to use, warm compresses and topical lubricants at baseline and during the study. These conventional treatments have been demonstrated to lower tear osmolarity. 30, 65 Honey is powerfully hyperosmotic due to its high concentration of sugars and low moisture content. 12, 13 When applied undiluted to the ocular surface in oedematous corneas, honey can rapidly (within 10 to 15 minutes) draw fluid from the corneal epithelium and anterior stroma, to temporarily clear an oedematous anterior cornea, resolve microcystic oedema and collapse epithelial bullae. 14, 15 Therefore, one concern with use of honey was that it may elevate tear osmolarity and induce ocular surface epithelial osmotic stress. To the contrary, both honey treatments and control in this study significantly lowered tear osmolarity (Table 5) , with the greatest decrease in measured tear electrolyte concentration across the three treatment arms occurring with the more concentrated Optimel 98 per cent product (Table 6 ). Osmotic concentration in this study was measured using the point of care TearLab test which uses a microelectrode to rapidly measure the number of charged particles in a tear sample 29 and therefore, not measure uncharged sugars. Hence, we are unable to determine the true effect of honey on tear osmolarity using this method. As measures of tear osmolarity were taken at least two hours after any eye drops (honey or lubricants) were instilled, the results of this study indicate that topical use of honey does not cause any long-term elevation of tear electrolyte concentration.
Limitations
The limitations of this study include the single site and lack of investigator and participant masking. Ophthalmic honey products have a distinctive colour, taste (via nasolacrimal drainage) and sting on instillation and hence, masking participants to treatment is problematic. Additionally, the use of a wet warm face cloth versus an external lid warming device that may more consistently regulate the elevation of temperature to the external lid 64, 65 is a further limitation. Similarly, we acknowledge the lack of regulation in technique, pressure and duration of the homebased 'lid massage' component of treatment compared with the use of an automated thermodynamic clinic-based treatment.
8 Regarding our choice of symptom tool, the Standard Patient Evaluation of Eye Dryness (SPEED survey) may correlate more with clinical parameters of evaporative dry eye 66 than the OSDI and may have been a more suitable instrument. Compliance was assessed only via patient logs versus strict compliance monitoring by measuring the volume of treatment of eye drops or gel used. Given the battery of tear film and ocular surface assessments performed in a single visit, we acknowledge that prior assessments may have influenced the results obtained for subsequent tests.
As data collection only occurred at baseline and Week 8, the initial time point where clinically significant improvements in symptoms and signs with treatment first occurred was not well defined, nor was it determined if clinical improvements were maintained after treatment cessation. Following on from this study, well-designed, masked multicentre clinical trials are required to confirm the therapeutic effects of Leptospermum spp. honey products in the management of evaporative dry eye due to MGD.
